|
Originally published In Press as doi:10.1074/jbc.M003990200 on June 8, 2000
J. Biol. Chem., Vol. 275, Issue 34, 26545-26550, August 25, 2000
Epidermal Growth Factor Receptor Transactivation Mediates
Substance P-induced Mitogenic Responses in U-373 MG Cells*
Ignazio
Castagliuolo ,
Leyla
Valenick,
Jennifer
Liu, and
Charalabos
Pothoulakis
From the Gastroenterology Division, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, Massachusetts 02215
Received for publication, May 10, 2000
 |
ABSTRACT |
Ligand-induced activation of G protein-coupled
receptors is emerging as an important pathway leading to the
activation of certain receptors with intrinsic tyrosine kinase
activity, such as the epidermal growth factor receptor (EGFR).
Substance P (SP) exerts many effects via activation of its G
protein-coupled receptor (neurokinin-1, NK-1). SP participates
in acute inflammation and activates key proteins involved in mitogenic
pathways, such mitogen-activated protein kinases (MAPKs), stimulating
DNA synthesis. We tested the hypothesis that SP-induced MAPK activation
and DNA synthesis require activation of the EGFR. In U-373 MG cells,
which express functional NK-1, SP induced tyrosine phosphorylation of
several proteins including EGFR. SP induced formation of an activated EGFR complex containing the adapter proteins SHC and Grb2, but not c-Src. SP activated the MAPK pathway as shown by increased Erk2
kinase activity. SP induced Erk2 activation, and DNA synthesis was
inhibited in cells transfected with a dominant negative EGFR plasmid
lacking kinase activity, as well as in cells treated with a specific
EGFR inhibitor. In addition, pertussis toxin, an inhibitor of
G protein subunits, prevented SP-induced EGFR
transactivation and subsequent DNA synthesis. Our results implicate
EGFR as an essential regulator in SP/NK-1-induced activation of the
MAPK pathway and cell proliferation in U-373 MG cells, and these events are mediated by a pertussis toxin-sensitive G protein. We suggest that this mechanism by which SP controls cell proliferation is an
important pathway in tissue restoration and healing.
 |
INTRODUCTION |
Substance P (SP),1 an
11-amino acid peptide member of the tachykinin family, is distributed
widely in the central and peripheral nervous systems (1). This peptide
exerts its effects by binding to its high affinity NK-1 receptor
subtype (SPR) (2). SP has been implicated in the regulation of
several physiologic and pathophysiologic processes such as pain, smooth
muscle contraction, and intestinal secretion (1). A large body of
in vitro and in vivo studies suggests a role for
SP as a proinflammatory agent. For example, SP is a chemoattractant for
monocytes (3, 4) and neutrophils (4), a stimulator of macrophage
phagocytosis (5), and mast cell degranulation (6). SP induces the
secretion of interleukin-1, interleukin-6, and tumor necrosis factor
from monocytes and macrophages (6, 7). In vivo studies
also showed that SP plays a pro-inflammatory role in acute intestinal
inflammation (8), acute pancreatitis (9), and lung disease (10).
Besides acting as a pro-inflammatory mediator and a neurotransmitter,
SP induces mitogenesis of several cell types including T lymphocytes
(11), skin fibroblasts (12), smooth muscle cells (12), and synoviocytes
(13). In addition, SP acts synergistically with growth factors to
stimulate skin fibroblast proliferation (14) and corneal epithelial
cell migration (15). Induction of mitogenesis and migration by SP
suggests a possible beneficial role for this peptide in tissue healing
during chronic inflammation. Indeed, several in vivo studies
show that SP and SPR are up-regulated during chronic inflammatory
disorders characterized by diffuse tissue damage (16, 17). Furthermore,
SP depletion by the neurotoxin capsaicin (18) or administration of a SP
antagonist (19) delay wound healing in experimental animals. However,
little is known about the mechanisms by which SP exerts its effects on
cell proliferation during wound healing and tissue restoration.
SP binding sites have been identified in the nervous system as well as
peripheral tissues such as in immune (3), epithelial (20), and
endothelial cells (16). Sequence analysis of the cloned NK-1 has
demonstrated that it belongs to the G protein-coupled receptor (GPCR)
family, and displays a typical 7-transmembrane-spanning domain
structure (21). The SPR has been shown to associate with a variety of
G protein isotypes, such as G 0/11,
G i, and G s (22, 23). Thus, SP
binding to SPR and consequent activation of G protein subunits results
in the activation of a variety of second messengers, including
inositol-3-phosphate kinase resulting in hydrolysis of
phosphoinositides, cAMP formation (24), and arachidonic acid release
(25). These events lead to mobilization of intracellular calcium and
enhancement of protein kinase activity, including protein kinase C
(24).
Mitogenic pathways are tightly regulated by a variety of molecular
events, most notably the phosphorylation/dephosphorylation of tyrosine
residues on several key effector proteins. Growth factors, such EGF and
platelet-derived growth factor, bind specifically to membrane receptors
with intrinsic tyrosine kinase activity, resulting in
autophosphorylation of the receptor. Once activated, such receptor
tyrosine kinases (RTKs) recruit adapter proteins to the cell plasma
membrane, forming an activated complex that initiates a signaling
cascade leading to nuclear translocation of transcription factors and
cell proliferation (26). Mitogenic mediators such as lysophosphatidic
acid (27), thrombin (27), angiotensin II (28), and SP (29),
which bind to GPCRs, ultimately activate similar signaling pathways.
Because GPCRs lack intrinsic kinase activity, transactivation of growth
factor receptors is a possible mechanism by which ligand binding to
GPCRs can activate mitogenic signal transduction pathways. For example,
the EGFR has been recently identified as an essential element in the
GPCR-mediated activation of MAPK-dependent pathways in
cells treated with various GPCR agonists (27). Moreover, angiotensin II
(30) and thrombin (31) stimulate phosphorylation of different growth
factor RTKs, suggesting that transactivation of distinct RTKs may
contribute to GPCR-mediated mitogenic signaling.
In this study, we sought to characterize the role of transactivation of
growth factor RTKs in SP-induced cell proliferation. Specifically, we
determined whether SP-induced EGFR activation can activate the MAPK
cascade and induce cell proliferation. Using U-373 MG cells, an
astroglioma cell line that expresses functional NK-1 receptors
(31-33), we found that nanomolar concentrations of SP cause
transphosphorylation of EGFR and the formation of an activated EGFR
complex containing specific adapter proteins. We demonstrate that
SP-induced MAPK activation and cell proliferation require the presence
of a functional EGFR kinase domain and involve a pertussis toxin
(PTX)-sensitive G protein. To our knowledge, these results represent
the first demonstration that transactivation of the EGFR is involved in
SP-induced cell proliferation.
 |
MATERIALS AND METHODS |
Cell Culture--
U-373 MG cells (ATCC, Rockville, MD) were
cultured in minimum essential medium containing 10% FCS, 1%
penicillin/streptomycin solution, 25 mM sodium bicarbonate,
and 10 mM sodium pyruvate (Sigma). CHO cells (ATCC)
were cultured in F-12 nutrient mixture containing 10% FCS, 1%
penicillin/streptomycin solution (Sigma).
Immunoprecipitation and Western Blotting--
U-373 MG cells
were cultured in complete medium, and when 75% confluent, they
were incubated for 18 h in medium containing 0% FCS. Cells
were then incubated with SP (10 nM) (29) or EGF (20 ng/ml)
for the indicated times. In some experiments, cells were preincubated
(18 h) with PTX (100 ng/ml) (Calbiochem). Monolayers were then washed
twice with ice-cold PBS and lysed (45 min on ice) using nondenaturing
RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH
7.4, 0.25% sodium deoxycholate, 0.1% Nonidet P-40, 100 µM NaVO4, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin). Particulate material was removed by centrifugation (15,000 × g for 5 min), and the supernatant was
collected. Protein concentrations were determined by the bicinichonic
acid method (Pierce). Lysates (2 mg/ml) were incubated with the
appropriate antibody (10 µg/mg cell lysate) for 2 h at 4 °C.
EGFR was precipitated with a mouse monoclonal antibody, whereas SHC and
c-Src were precipitated with rabbit polyclonal antibodies (1 µg of
antibody/200 µg of whole cell lysate for all above
immunoprecipitates) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Protein A-agarose or protein G Plus-agarose (50 µl, Santa Cruz
Biotechnology, Inc.) was added to the mixture and incubated for 1 h at 4 °C. Beads were washed twice by centrifugation (20 s,
12,000 × g) with ice-cold RIPA buffer followed by one
wash with ice-cold PBS and then boiled (5 min) in 30 µl of sample
loading buffer (62.5 mM Tris, pH 6.8, 10% glycerol, 2%
SDS, 5% -mercaptoethanol, and 0.1% bromphenol blue).
Immunoprecipitated proteins were fractionated on a SDS-PAGE gel and
then transferred and immobilized onto a nitrocellulose membrane.
Membranes were blocked overnight at 4 °C in 5% skim milk in
phosphate-buffered saline (pH 7.4) containing 0.05% Tween-20 and then
incubated with the appropriate antibodies. Phosphorylated tyrosine
residues were identified using the PY99 antibody (1:1000 dilution), and
SHC proteins were identified using a rabbit polyclonal antibody
(1:1000 dilution) (Santa Cruz Biotechnology, Inc.). Grb2 proteins were
identified using a mouse monoclonal antibody (1:5000 dilution)
(Transduction Laboratories; Lexington, KY). Immunocomplexes were
visualized using the ECL Western blotting detection reagents (Amersham
Pharmacia Biotech).
Immunocytochemistry on Cultured Cells--
Cells were plated on
sterile coverslips at a density of 100,000 cells/ml and cultured in
complete media. After 24 h, medium containing 0.5% FCS was
placed on the cells overnight. Cells were stimulated with SP (10 nM) for the indicated time periods, followed by two washes
with ice-cold PBS. The following procedures were done at room
temperature using PBS at a pH of 7.4 unless otherwise stated. Cells
were then fixed on the coverslip using 4% paraformaldehyde in PBS for
10 min and then washed (three times for 10 min with PBS). Cells were
then permeabilized by incubation with 0.2% Triton X-100 in PBS for 5 min. The Triton X mixture was removed, and free aldehyde groups were
inactivated by the addition of 0.5 mg/ml sodium borohydride in PBS for
10 min and then washed (three times for 5 min with PBS). Cells were
then incubated in 3.0% bovine serum albumin in PBS for 1 h to
block any nonspecific binding. Cells were then probed with 4 ng/ml
antiphosphotyrosine antibody (Santa Cruz Biotechnology, Inc.) in PBS
containing 1% bovine serum albumin for 40 min, followed by washing
(three times for 5 min with PBS). Antiphosphotyrosine antibodies were
then detected by the addition of donkey anti-mouse rhodamine-labeled
antibody for 40 min (Jackson Immunoresearch Laboratories, West Grove,
PA). Excess rhodamine-labeled antibody was removed by washing (three times for 5 min with PBS). Coverslips were then mounted, and proteins phosphorylated on tyrosine residues were visualized using a confocal microscope (Model MRC1024, Bio-Rad) with Plan-Neofluar objective (100×). Images were digitally stored in Bio-Rad COMOS software.
Transfection Experiments--
U-373 MG cells were transfected
using a modified CaPO4/DNA precipitation procedure (34).
Briefly, cells were plated at a density of 25,000 cells/ml and cultured
for 24 h. Two hours prior to transfection, the medium was replaced
with fresh medium. Then, a total of 2.5 µg of plasmid DNA/ml
of medium was introduced to the cells. After 18 h, the
medium was removed, and cells were washed twice with PBS and cultured
in complete medium for the indicated period of time.
Preliminary experiments showed that the transfection efficiency
(evaluated by expression of green fluorescent protein (In vitrogen)) in
cells transfected with pCHER (35) and selected with methotrexate (10 mM), was ~30-40%, whereas the efficiency was improved
to over 90% by co-transfection with pSP73 (Promega) a plasmid carrying
a neomycin resistance gene (data not shown).
In Vitro Kinase Assays--
Erk2 in vitro kinase
activity was determined as described previously by Daub et
al. (36). Briefly, mock and pCHER transfected U-373 cells (75%
confluent) were treated with SP (10 nM) for 7 min or EGF
(10 ng/ml) for 3 min. Erk2 proteins were immunoprecipitated from the
RIPA soluble lysates using rabbit polyclonal antibodies (Santa Cruz
Biotechnology, Inc.). The immunoprecipitates were then washed twice in
RIPA and once in kinase buffer (20 mM Hepes, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 200 µM sodium orthovanidate). Kinase reactions were performed
immediately in a 30-µl volume of kinase buffer containing 0.5 mg/ml
myelin basic protein (Sigma), 50 µM unlabeled ATP, and 1 µCi/ml [ -32P]ATP (NEN Life Science Products).
After 10 min at 37 °C, reactions were stopped by the addition of 30 µl of 2× sample buffer. Reactions were then subjected to
electrophoresis on a 12% SDS-PAGE gel. Gels were dried, and
phosphorylated myelin basic protein was identified by audoradiography.
Proliferation Assay--
DNA proliferation assays were performed
as described previously (37). Briefly, U-373 MG cells were plated at
25,000/cm2 in 6-well plates, and after 24 h cells were
either mock-transfected or transfected with pCHER (2.0 µg/well) and
pSP73 (0.5 µg/well), which contains a neomycin resistance gene. Cells
were washed twice with PBS after 18 h and then cultured in
complete medium containing geneticin (1 mg/ml) to select for
transfected cells. After 48 h, medium was removed, and cells were
cultured overnight in medium containing no FCS. In some
experiments mock-transfected cells were incubated in the presence of 1 µM tyrphostin AG1478 (Calbiochem) for 15 min before
stimulation. Cells were then stimulated (6 h at 37 °C) with SP (10 nM) or EGF (10 ng/ml) in the presence of [3H]thymidine (0.5 µCi/well). Cells were washed (three
times) with ice-cold PBS and then lysed with 0.3 M NaOH,
and [3H]thymidine incorporation was determined by
scintillation counting. DNA synthesis was expressed as counts/min.
In separate experiments, control CHO cells, a cell line that does not
express functional EGFR, and CHO cells stably expressing the human NK-1
receptor (a kind gift of Dr. Nick Boyd, Boston University Medical
School, Boston, MA) were transfected with pEGFR (a kind gift of Dr.
David Levy, New York University) using the same procedure as stated
above. DNA proliferation assays in response to SP were performed as
described above.
 |
RESULTS |
Substance P Induces Tyrosine Phosphorylation of Distinct Proteins
in U-373 MG Cells--
U-373 MG cells express functional NK-1 (32, 33)
and release inflammatory cytokines when exposed to SP (38). In basal conditions, few proteins in U-373 MG cells appear to be
tyrosine-phosphorylated (Fig. 1). Upon
treatment with SP (10 nM), at least four distinct protein
bands showed increased tyrosine phosphorylation by Western blot (Fig.
1). Increased protein tyrosine phosphorylation was detected as early as
2 min after exposure to SP, and several proteins remained
phosphorylated for up to 1 h. Similarly, immunocytochemical analysis demonstrated that only a few proteins were
tyrosine-phosphorylated in unstimulated cells (Fig.
2A). However, at 30, 60, and
90 min, there was a dramatic increase of phosphorylated tyrosine
residues localized in the nucleus, as well as on the cell's outer
membrane (Fig. 2, B-D). These data, taken together,
demonstrate the ability of SP to induce phosphorylation of proteins on
tyrosine residues, even though NK-1 lacks intrinsic kinase activity
(2).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
SP induces tyrosine phosphorylation of
multiple proteins in U-373 MG cells. SP (10 nM) was
incubated with cells for the indicated time periods. Cells were then
lysed with RIPA buffer, and equal amounts of protein were fractionated
on a 7.5% SDS-PAGE gel. Proteins phosphorylated on tyrosine residues
were identified using an antiphosphotyrosine antibody and detected
using ECL reagents. Data presented are representative of three
different experiments.
|
|

View larger version (143K):
[in this window]
[in a new window]
|
Fig. 2.
SP induces phosphorylation of tyrosine
residues in U-373 MG cells. Cells were cultured on coverslips and
then incubated without (A) or with SP (10 nM)
for 30 (B), 60 (C), or 90 (D) min.
Cells were fixed and subject to immunocytochemistry. Proteins
phosphorylated on tyrosine residues were identified using an
antiphosphotyrosine antibody and visualized using confocal microscopy.
The amount of phosphorylated tyrosine residues increases dramatically
and time dependently in response to SP. Phosphorylated proteins appear
to be localized mainly in focal regions of the plasma membrane and in
the nucleus.
|
|
Substance P Transactivates EGFR--
Because the NK-1 is a GPCR
and recent studies have indicated that GPCRs can transactivate RTKs, we
examined the effect of SP on EGFR. As shown in Fig.
3A, SP at nanomolar
concentrations induced a transient and biphasic increase in tyrosine
phosphorylation of EGFR in U-373 MG cells. EGFR tyrosine
phosphorylation was detectable as early as 2 min after SP exposure and
returned to control levels at 5-7 min. EGFR tyrosine phosphorylation
was elevated again at 10-15 min and began to diminish at 30 min (Fig.
3A).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
SP induces tyrosine phosphorylation of EGFR
and the formation of an activated EGFR complex containing the adapter
proteins SHC and Grb2. U-373 MG cells incubated with SP (10 nM) for the indicated time periods were lysed with RIPA
buffer. Soluble proteins were immunoprecipitated with either an
anti-EGFR antibody (A, B, and D) or an
anti-SHC antibody (C). Proteins were fractionated on a 7.5%
SDS-PAGE gel, and proteins were detected using either an
antiphosphotyrosine antibody (A, B, and
C) or an anti-Grb2 antibody (D). A, SP
induces increased tyrosine phosphorylation of EGFR and multiple
co-precipitating proteins in a time-dependent manner.
B, SP induces increased association of the adapter protein
SHC with the EGFR in a time-dependent manner. C,
SP induces tyrosine phosphorylation of the three isoforms of the
protein SHC. D, SP induces the association of the adapter
protein Grb2 with the EGFR in a time-dependent manner. Data
presented are representative of four different experiments that give
similar results.
|
|
Ligand-induced autophosphorylation of EGFR causes recruitment of
adapter proteins such as SHC, Grb2, Sos, and Src family kinases to the
cytoplasmic domain of EGFR (26). As shown in Fig. 3, SP induces
tyrosine phosphorylation of several proteins that co-precipitated with
EGFR. To identify the proteins co-precipitating with EGFR, blots were
stripped and reprobed with anti-SHC, Grb2, and c-Src antibodies.
Increased association with activated EGFR (Fig. 3B) and
tyrosine phosphorylation (Fig. 3C) of SHC in response to SP was detected. Furthermore, the adapter protein Grb2 was also associated with the activated EGFR complex in response to SP (Fig. 3D).
However, there was no increase in the amount of c-Src associated with
the EGFR complex, and no tyrosine phosphorylation of c-Src in response to SP was evident (data not shown).
SP Induces Kinase Activity of Erk2 via Transactivation of the
EGFR--
The association between Grb2 and EGFR is an essential step
in the activation of the Ras/mitogen-activated protein kinase pathway, ultimately initiating DNA synthesis. Because SP triggers both EGFR
transactivation and MAPK activation, we tested the functional role of
EGFR in SP-induced activation of the MAPK Erk2. As determined by
increased phosphorylation of myelin basic protein in vitro, Erk2 was activated following U-373 MG stimulation with SP and with the
RTK ligand EGF (Fig. 4). In cells
transfected with a dominant negative EGFR plasmid lacking kinase
activity (pCHER), however, Erk2 activation by both SP and EGF was
considerably inhibited (Fig. 4).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
SP- induced MAPK activity requires
transactivation of the EGFR. U-373 MG cells were either
mock-transfected or transfected with pCHER, serum-starved overnight,
and treated without or with either SP (10 nM) for 10 min or
EGF (10 ng/ml) for 3 min. Cells were lysed with RIPA buffer, and Erk2
proteins were precipitated using an anti-Erk2 antibody. Kinase
reactions were performed using the immunoprecipitated proteins in the
presence of myelin basic protein (MBP) as substrate for Erk2
kinases and [32P]ATP. Reactions were loaded onto a 12%
SDS-PAGE gel, and Erk2 activity was determined by autoradiography. In
mock-transfected cells (lanes 1-3), SP (lane 2),
and EGF (lane 3) induced Erk2 kinase activity when compared
with control (lane 1). In cells transfected with pCHER
(lanes 4-6), SP (lane 5), and EGF (lane
6) induced Erk2 kinase activity is greatly inhibited when compared
with respective nontransfected cells (lanes 2 and
3). This suggests that the presence of a dominant negative
EGFR lacking kinase activity partially inhibits SP- and EGF-induced
MAPK activity. Data presented are representative of three different
experiments.
|
|
SP-induced DNA Synthesis Is Mediated through EGFR
Transactivation--
To further determine the functional role of
SP-induced EGFR tyrosine phosphorylation and activation, we tested the
effect of pCHER and tyrphostin AG1478 (a specific inhibitor of EGFR) on
SP-induced DNA synthesis. As shown in Fig.
5A, SP and EGF induced DNA
synthesis in mock-transfected U-373 MG cells as indicated by increased
[3H]thymidine incorporation. SP- and EGF-induced DNA
synthesis was significantly inhibited in pCHER-transfected U-373 MG
cells. Furthermore, incubation of cells with tyrphostin AG1478 almost
completely inhibited both SP- and EGF-induced DNA synthesis (Fig.
5A). The requirement for EGFR in SP-induced DNA synthesis
was also tested in CHO cells that do not normally express either NK-1
and EGF receptors. In these experiments CHO cells were
mock-transfected, transfected with NK-1 alone, or with NK-1 and EGFR
together, and then SP-induced DNA synthesis was determined. As shown in
Fig. 5B, SP and EGF did not stimulate DNA synthesis in
either normal CHO cells or CHO cells expressing NK-1. However, in CHO
cells expressing NK-1 and EGFR, exposure to SP significantly increased
DNA synthesis (Fig. 5B). These data indicate that
the kinase activity of the EGFR is required for SP to induce DNA
synthesis.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
SP-induced DNA synthesis requires
transactivation of the EGFR. A, mock- or
pCHER-transfected U-373 MG cells were serum-starved and, where
indicated, incubated for 15 min with tyrphostin AG1478 (T-1478) (1 µg/ml), before exposure to SP (10 nM) or EGF (10 ng/ml).
Cells were incubated in the presence of [3H]thymidine
(0.5 µCi/well) for 6 h. Cells were collected and placed in
scintillation vials to determine [3H]thymidine
incorporation, and the results were expressed as counts/min
(cpm). As expected, SP and EGF significantly increased DNA
synthesis in mock-transfected cells. SP- and EGF-induced DNA
synthesis in mock-transfected cells was significantly inhibited in the
presence of tyrphostin. In cells transfected with pCHER, SP- and EGF-
induced DNA synthesis was significantly prevented. This suggests that
inhibition of EGFR kinase activity prevents SP- and EGF- induced DNA
synthesis. Data are expressed as mean ± S.E. and are
representative of four different experiments each with triplicate
determinations. * indicates p < 0.01 versus control in
mock-transfected cells, + indicates p < 0.01 versus SP-treated mock transfected cells. B, mock
or pEGFR-transfected control and NK-1-transfected CHO cells were
serum-starved for 18 h and then exposed to SP (10 nM)
or EGF (10 ng/ml) in the presence of [3H]thymidine (0.5 µCi/well). [3H]Thymidine incorporation was determined
after 6 h, and results were expressed as counts/min (cpm). SP and
EGF failed to stimulate DNA synthesis in CHO cells expressing the NK-1
receptor, whereas SP significantly increased DNA synthesis in CHO cells
co-expressing NK-1 and EGFR. Data are expressed as mean ± S.E.
and are representative of four different experiments each with
triplicate determinations. * indicates p < 0.01 versus
control in mock- and EGFR-transfected CHO cells.
|
|
A PTX-sensitive G Subunit Is Involved in SP-induced
Transactivation of EGFR--
NK-1 associates with several G protein
subunits such as Gq/11, G o, and
G s (22, 23). We next determined whether SP-mediated EGFR
activation and subsequent DNA synthesis was mediated through a
PTX-sensitive G subunit. As shown in Fig.
6, pretreatment of cells with PTX
completely prevented SP-induced EGFR tyrosine phosphorylation. In
addition, SP-induced DNA synthesis was inhibited by pretreatment of
cells with PTX (Fig. 7), whereas PTX had
no effect on EGF-induced DNA synthesis. These results suggest that SP-induced activation of EGFR involves a PTX-sensitive G
subunit.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
SP-induced EGFR phosphorylation requires a
PTX-sensitive G subunit. U-373 MG cells
were serum-starved and incubated with PTX overnight. Cells were then
exposed to either SP (10 nM) or EGF (10 ng/ml) for 10 or 7 min, respectively. Cells were then lysed with RIPA buffer, and soluble
proteins were subjected to immunoprecipitation with an anti-EGFR.
Proteins were then fractionated on a 7.5% SDS-PAGE gel and detected
using an antiphosphotyrosine antibody. SP (lane 4) and EGF
(lane 2) both increased EGFR phosphorylation as compared
with control (lane 1), whereas pretreatment of
cells with PTX completely prevented SP-induced EGFR tyrosine
phosphorylation (lane 5). PTX had no effect on
EGF-induced EGFR phosphorylation (lane 3). Data
presented are representative of three different experiments that give
similar results.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
SP-induced DNA synthesis requires a
PTX-sensitive G subunit. U-373 MG cells
were serum-starved and incubated with PTX overnight. Then they were
incubated with SP (10 nM) or EGF (10 ng/ml) in the presence
of [3H]thymidine (0.5 µCi/well). After 6 h, cells
were washed, scraped, and placed in scintillation vials to determine
[3H]thymidine incorporation. Results were expressed as
counts/min (cpm). SP and EGF significantly increased DNA
synthesis over control. SP-induced DNA synthesis was completely
prevented by PTX treatment, whereas PTX had no significant effect on
EGF induced DNA synthesis. Data are expressed as mean ± S.E. and
are representative of three different experiments each with triplicate
determinations. * indicates p < 0.01 versus
SP-treated control cells.
|
|
 |
DISCUSSION |
The rapid phosphorylation and consequent activation or
inactivation of proteins leading to DNA synthesis generally
characterizes growth factor-mediated cell proliferation (26). The
peptide SP stimulates mitogenesis in various cell types including human astrocytoma cell lines (29, 32) and activates pathways involving protein kinase signaling such as MAPKs (29). Here we report for the
first time that SP binding to its NK-1 receptor induces transactivation of EGFR. We also present evidence that SP-induced MAPK
activation and mitogenesis involves the formation of an activated EGFR
signaling complex.
Upon ligand binding, the dimerized EGFR activates a sequence of
phosphorylation events initiated by autophosphorylation. Activated EGFR
creates a docking area for adapter proteins such as Grb2, Sos, and SHC
(11). Formation of such a complex on the intracellular domain of EGFR
activates the Ras/Raf signaling pathway, resulting in MAPK activity
(39). Recently, several GPCR agonists have been shown to transactivate
RTKs, such as the EGFR, by inducing tyrosine phosphorylation and
association of adapter proteins (40). For example, Daub et
al. (27) recently reported that lysophosphatidic acid or thrombin
binding to their GPCRs induce EGFR tyrosine phosphorylation and its
association with activated Grb2. We show that SP causes a
biphasic tyrosine phosphorylation of EGFR (Fig. 3A) and its association with SHC and Grb2 (Fig. 3, B and D,
respectively). Recent studies also suggest that EGF-induced EGFR
activation may complex with Src tyrosine kinase and that this
interaction is required for MAPK activation (41). Although we did not
demonstrate any association of c-Src with EGFR following SP-mediated
transactivation, we cannot exclude that other Src family kinases
(i.e. fyn, lck, yes) are involved.
Besides its well known effects as a neurotransmitter and inflammatory
mediator, SP has been recently recognized as a mitogenic factor.
SP-induced mitogenesis has been described in several cell types,
suggesting that this effect may be relevant in physiological or
pathological conditions. The functional role of SP-induced EGFR
transactivation was investigated using a dominant-negative EGFR
construct lacking kinase activity (pCHER) (35) and by co-expressing EGF
and NK-1 receptors in CHO cells. Previous studies indicate that SP is
capable of inducing MAPK activation (29). MAPKs such as Erk1 and Erk2
are key components of signaling pathways involved in the regulation of
cell growth and differentiation, mediating such events as
c-fos induction and DNA synthesis (42, 43). In our
system, SP-induced Erk2 kinase activity and cell proliferation were
drastically inhibited in U-373 MG cells transfected with pCHER or
treated with an EGFR pharmacological inhibitor. Previous studies also
reported that SP-induced cell proliferation was substantially inhibited
in the presence of tyrosine kinase inhibitors (29). The inability of
pCHER to completely prevent SP or EGF-induced Erk2 kinase activity in
our experiments is probably because of a transfection efficiency of
less than 100% in the U-373 MG cells (data not shown). Furthermore,
previous studies indicated that LPA- and thrombin-induced DNA synthesis
was only partially inhibited by a specific EGFR inhibitor (27). It is
possible that different signaling pathways activated by SP lead to MAPK
activation and cell proliferation, because SP-induced EGFR
phosphorylation in U-373 MG cells in our experiments was biphasic (Fig.
3A). Several pathways may be involved in the mechanism of
NK-1 receptor and EGFR trans-activation. For example, stimulation of G
protein-coupled receptors can induce transactivation of EGFR
trough activation of transmembrane metalloproteinases leading to the
extracellular processing of a transmembrane growth factor precursor and
release of the mature growth factor, which interacts with the binding domain of the EGFR (44). Furthermore GPCR agonists (LPA, thrombin, and
SP) may regulate proliferative responses via activation of different RTKs, ion channels, or regulation of second messenger systems
(45).
When GPCR ligands bind to their receptor, G proteins associated with
the cytoplasmic portion of the receptor become activated (46). In the
inactive form, three G protein subunits ( , , and ) associate
with each other, and the subunit is constitutively bound to GDP.
Once activated, the subunit exchanges GDP for GTP and the 
subunit dissociates, allowing the monomer subunit and the dimer
 subunit to initiate various metabolic pathways by activating
specific second messengers. There are four subfamilies of subunits
grouped together based on sequence homology: o, i, q, and 12. An
increasing number of reports have indicated that certain isoforms of G
protein subunits can activate the MAPK pathway. For example, Van
Brunsen et al. (47) demonstrated that G subunits
activate MAPKs by a pathway common to RTKs containing an activated
Shc-Grb2-Sos complex, whereas Daub et al. (36) reported that
both G q and G i proteins coupled to GPCRs
can promote activation of the MAPK pathway. The exact nature of the G
subunit(s) involved in SP/SPR signal transduction is not completely
lucid. So far, G q/ll, G s, and
G o protein subunits have been shown to associate with
the SPR (23). Because PTX pretreatment completely abolished SP-induced
EGFR phosphorylation and subsequent DNA synthesis in U-373 MG cells,
our results suggest that a PTX-sensitive G i subunit
mediates these events. Activated G i subunits have been implicated in SPR-mediated increases in arachidonic acid levels (48).
Indeed, SP stimulates arachidonic acid metabolism into prostaglandins
primarily of the PGE2 family that have been implicated in mitogenic
activities such as fibroblast growth (25) and angiogenesis (49).
However, it is unknown whether the pathways by which SP induces
arachidonic acid metabolism and EGFR tyrosine phosphorylation converge
to stimulate DNA synthesis and cell proliferation.
Cell attachment and migration, proliferation, and differentiation are
the three steps involved in wound healing. Although SP is a potent
positive regulator of cell proliferation, SP activity has also been
correlated with cell attachment and migration, and, more loosely, with
cellular differentiation. SP, in synergy with insulin-like growth
factor-1, has been shown to induce rabbit corneal epithelial cell
attachment to fibronectin matrix, promote subsequent migration, and
increase levels of the integrins 5 and
1 mRNA (50, 51). Furthermore, SP has been implicated in angiogenesis by inducing the formation of capillary-like structures from endothelial cells placed on a Matrigel matrix (52). Thus, SP may
play an important role in many processes associated with wound healing.
Our observations demonstrating a "cross-talk" between NK-1 receptor
and EGFR in cell proliferation may be pathophysiologically relevant
because up-regulation of both NK-1 and EGFR occurs during diseases
characterized by ulcer formations. For example, NK-1 and EGFR protein
and mRNA levels are up-regulated in the colonic mucosa of patients
with chronic inflammatory disorders such as inflammatory bowel disease
(16, 53).
Although a cross-talk between NK-1 and EGFR during chronic inflammatory
processes may be an important mechanism in stimulating tissue healing,
enhanced sensitivity to SP-induced proliferative effects may eventually
lead to aberrant growth and neoplasia formation. Indeed, many chronic
inflammatory diseases, such as ulcerative colitis, are associated with
a high incidence of cancer (54). In addition, blood vessels surrounding
human colorectal cancers overexpress NK-1 (55). Furthermore, target
genes of SP have been shown to include certain oncogenes such as
c-myc, a well documented promoter of cell growth
(29). As demonstrated by Luo et al. (29), SP is able to
increase expression of c-myc mRNA and protein
levels in U-373 MG cells. Understanding the mechanisms by which SP and
NK-1 activate genes and proteins involved in cell growth and
proliferation may provide insights into the possible involvement of
SP/NK-1 in carcinogenesis.
In conclusion, we report for the first time that SP, acting via the
NK-1, is able to induce formation of an activated EGFR complex
containing the adapter proteins SHC and Grb2. SP-induced kinase
activity of the MAPK Erk2, as well as SP-induced DNA synthesis, require
functional EGFR kinase activity. Finally, SP-induced EGFR transactivation and subsequent DNA synthesis occurs via activation of a
PTX-sensitive G i subunit. These data suggest that the
signaling pathways between SP receptor and growth factor RTKs converge
at a very upstream point, increasing the possible pathways by which SP
may tightly control the intracellular mechanisms leading to cell
proliferation, and eventually, tissue restoration.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Beth Israel Deaconess
Medical Center, Division of Gastroenterology, Dana 501, 330 Brookline
Ave., Boston, MA 02215. Tel.: 617-667-1259; Fax: 617-667-2767; E-mail:
icastagl@ux1.unipd.it.
Published, JBC Papers in Press, June 8, 2000, DOI 10.1074/jbc.M003990200
 |
ABBREVIATIONS |
The abbreviations used are:
SP, substance P;
GPCR, G protein-coupled receptor;
EGF, epidermal growth factor;
RTK, receptor tyrosine kinases;
PTX, pertussis toxin;
FCS, fetal calf serum;
PBS, phosphate-buffered saline;
RIPA, radioimmune precipitation buffer;
PAGE, polyacrylamide gel electrophoresis;
Erk, extracellular
signal-regulated kinase;
MAPK, mitogen-activated protein kinase;
CHO, Chinese hamster ovary;
NK-1, neurokinin-1;
SPR, substance P
receptor.
 |
REFERENCES |
| 1.
|
Pernow, B.
(1983)
Pharmacol. Rev.
35,
85-89
|
| 2.
|
Nakanishi, S.
(1991)
Annu. Rev. Neurosci.
14,
123-136
|
| 3.
|
Ruff, M. R.,
Wahl, S. M.,
and Pert, C. B.
(1985)
Peptides (Elmsford)
2 (suppl.),
107-110
|
| 4.
|
Weidermann, C. J.,
Weidermann, F. J.,
Apperl, A.,
Keiselback, G.,
Konwalinka, G.,
and Braunsteiner, H.
(1989)
Naunyn-Schmiedeberg's Arch. Pharmacol.
340,
185-191
|
| 5.
|
Bar-Shavit, Z.,
Goldman, R.,
Stabinsky, Y.,
Gottlieb, P.,
Fridkin, M.,
Teichberg, V. I.,
and Blumberg, S.
(1980)
Biochem. Biophys. Res. Commun.
30,
1445-1451
|
| 6.
|
Brain, S. D.
(1997)
Immunopharmacology
37,
133-152
|
| 7.
|
Castagliuolo, I.,
Keates, A. C.,
Qiu, B.,
Kelly, C. P.,
Nikulasson, S.,
Leeman, S. E.,
and Pothoulakis, C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4788-4793
|
| 8.
|
Castagliuolo, I.,
Riegler, M.,
Pasha, A.,
Nikulasson, S.,
Lu, B.,
Gerard, C.,
Gerard, N. P.,
and Pothoulakis, C.
(1998)
J. Clin. Invest.
101,
1547-1550
|
| 9.
|
Bhatia, M.,
Saluja, A. K.,
Hofbauer, B.,
Frossard, J. L.,
Lee, H. S.,
Castagliuolo, I.,
Wang, C.,
Gerard, N.,
Pothoulakis, C.,
and Steer, M. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4760-4765
|
| 10.
|
Bosic, C. R.,
Lu, B.,
Hopken, U. T.,
Gerard, C.,
and Gerard, N. P.
(1996)
Science
273,
1722-1725
|
| 11.
|
Payan, D. G.,
Brewster, D. R.,
and Goetzl, E. J.
(1983)
J. Immunol.
131,
1613-1615
|
| 12.
|
Nilsson, J.,
von Euler, A. M.,
and Dalsgaard, C. J.
(1985)
Nature
315,
61-63
|
| 13.
|
Lotz, M.,
Carlson, D. A.,
and Vaughn, J. H.
(1987)
Science
235,
893-895
|
| 14.
|
Kahler, C. M.,
Herold, M.,
Reinisch, N.,
and Wiedermann, C. J.
(1996)
J. Cell. Physiol.
166,
601-608
|
| 15.
|
Nakamura, M.,
Nishida, T.,
Ofuji, K.,
Reid, T. W.,
Mannis, M. J.,
and Murphy, C. J.
(1997)
Exp. Eye. Res.
65,
321-329
|
| 16.
|
Mantyh, C. R.,
Gates, T. S.,
Zimmermann, R. P.,
Welton, M. L.,
Pasaro, E. P.,
Vigna, S. R.,
Maggio, J. E.,
Kruger, L.,
and Mantyh, P. W.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
3235-3239
|
| 17.
|
Sharkey, K. A.
(1992)
Ann. N. Y. Acad. Sci.
664,
425-442
|
| 18.
|
Kjartansson, J.,
Dalsgaard, C. J.,
and Honsson, C. E.
(1987)
Plast. Reconstr. Surg.
79,
218-221
|
| 19.
|
Benrath, J.,
Zimmerman, M.,
and Gillardon, F.
(1995)
Neurosci. Lett.
200,
17-20
|
| 20.
|
Pothoulakis, C.,
Castagliuolo, I.,
Li, H.,
Wang, C.,
Hoffman, B. J.,
LaMont, J. T.,
Leeman, S.,
and Mezey, E.
(1998)
Am. J. Physiol.
275,
G68-G75
|
| 21.
|
Hershey, A. D.,
and Krause, J. E.
(1990)
Science
247,
958-962
|
| 22.
|
Nishimura, K.,
Frederick, J.,
and Kwatra, M. M.
(1998)
J. Recept. Signal Transduct. Res.
18,
51-65
|
| 23.
|
Roush, E. D.,
and Kwatra, M. M.
(1998)
FEBS Lett.
428,
291-294
|
| 24.
|
Otsuka, M.,
and Yoshioka, K.
(1993)
Physiol. Rev.
73,
229-308
|
| 25.
|
Kahler, C. M.,
Herold, M.,
and Wiedermann, C. J.
(1993)
J. Cell. Physiol.
156,
579-587
|
| 26.
|
Pazin, M. J.,
and Williams, L. T.
(1992)
Trends Biochem. Sci.
17,
374-378
|
| 27.
|
Daub, H.,
Weiss, F. U.,
Wallasch, C.,
and Ullrich, A.
(1996)
Nature
379,
557-560
|
| 28.
|
Li, X.,
Lee, J. W.,
Graves, L. M.,
and Earp, H. S.
(1998)
EMBO J.
17,
2574-2583
|
| 29.
|
Luo, W.,
Sharif, T. R.,
and Sharif, M.
(1996)
Cancer Res.
56,
4983-4991
|
| 30.
|
Linseman, D. A.,
Benjamin, C. W.,
and Jones, D. A.
(1995)
J. Biol. Chem.
270,
12563-12568
|
| 31.
|
Rao, G. N.,
Delafontaine, P.,
and Runge, M. S.
(1995)
J. Biol. Chem.
270,
27871-27875
|
| 32.
|
Eistetter, H. R.,
Mills, A.,
Brewester, R.,
Alouani, S.,
Rambosson, C.,
and Kawashima, E.
(1992)
Glia
6,
89-95
|
| 33.
|
Lee, C. M.,
Kum, W.,
Cockram, C. S.,
Teoh, R.,
and Young, J. D.
(1989)
Brain Res.
488,
328-331
|
| 34.
|
Hauck, W.,
and Stanners, C. P.
(1995)
J. Biol. Chem.
270,
3602-3610
|
| 35.
|
Prywes, R.,
Livneh, E.,
and Schlessinger, J.
(1986)
EMBO J.
5,
2179-2190
|
| 36.
|
Daub, H.,
Wallasch, C.,
Lankenau, A.,
Herrlich, A.,
and Ullrich, A.
(1997)
EMBO J.
16,
7032-7044
|
| 37.
|
Binion, D. G.,
West, G. A.,
Ina, K.,
Ziats, N. P.,
Emancipator, S. N.,
and Fiocchi, C.
(1997)
Gastroenterology
112,
1895-1907
|
| 38.
|
Palma, C.,
Urbani, F.,
and Manzini, S.
(1995)
J Neuroimmunol.
59,
155-163
|
| 39.
|
Medema, R. H.,
and Bos, J. L.
(1993)
Crit. Rev. Oncog.
4,
615-661
|
| 40.
|
Diverse-Pierluissi, M.,
Remmers, A. E.,
Neubig, R. R.,
and Dunlap, K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5417-5421
|
| 41.
|
Luttrell, L. M.,
Della Rocca, G. J.,
van Biesen, T.,
Luttrell, D. K.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
4637-4644
|
| 42.
|
Egan, S. E.,
and Weinberg, R. A.
(1993)
Nature
365,
781-783
|
| 43.
|
Sharif, M.,
Sasakawa, N.,
and Hanley, M. R.
(1994)
Mol. Cell. Endocrinol.
100,
115-119
|
| 44.
|
Prenzel, N.,
Zwick, E.,
Daub, H.,
Leserer, M.,
Abraham, R.,
Wallasch, C.,
and Ullrich, A..
(1999)
Nature
402,
884-888
|
| 45.
|
Lopez-Ilasaca, M.
(1998)
Biochem. Pharmacol.
56,
269-277
|
| 46.
|
Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
1839-1842
|
| 47.
|
Van Brunsen, T.,
Hawes, B. E.,
Luttrell, D. K.,
Krueger, K. M.,
Touhara, K.,
Porfiri, E.,
Sakaue, M.,
Luttrell, L. M.,
and Lefkowitz, R. J.
(1995)
Nature
376,
781-784
|
| 48.
|
Garcia, M.,
Sakamoto, K.,
Shigekawa, M.,
Nakanishi, S.,
and Ito, S.
(1994)
Biochem. Pharmacol.
48,
1735-1741
|
| 49.
|
Chiarugi, V.,
Magnelli, L.,
and Gallo, O.
(1998)
Int. J. Mol. Med.
2,
715-719
|
| 50.
|
Nakamura, M.,
Chikama, T.,
and Nishida, T.
(1999)
Br. J. Pharmacol.
127,
489-497
|
| 51.
|
Nakamura, M.,
Chikama, T.,
and Nishida, T.
(1998)
Biochem. Biophys. Res. Commun.
246,
777-782
|
| 52.
|
Wiedermann, C. J.,
Auer, B.,
Sitte, B.,
Reinisch, N.,
Schratzberger, P.,
and Kahler, C. M.
(1996)
Eur. J. Pharmacol.
298,
335-338
|
| 53.
|
Galandiuk, S.,
Miseljic, S.,
Yang, A. R.,
Early, M.,.,
McCoy, M. D.,
and Wittliff, J. L.
(1993)
Arch. Surg.
128,
637-642
|
| 54.
|
Solomon, M. J.,
and Schnitzler, M.
(1998)
World J. Surg.
22,
352-358
|
| 55.
|
Reubi, J. C.,
Mazzucchelli, L.,
Hennig, I.,
and Laissue, J. A.
(1996)
Gastroenterology
110,
1719-1726
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Chernova, J.-P. Lai, H. Li, L. Schwartz, F. Tuluc, H. M. Korchak, S. D. Douglas, and L. E. Kilpatrick
Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R)
J. Leukoc. Biol.,
January 1, 2009;
85(1):
154 - 164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Ramnath, J. Sun, S. Adhikari, L. Zhi, and M. Bhatia
Role of PKC-{delta} on substance P-induced chemokine synthesis in pancreatic acinar cells
Am J Physiol Cell Physiol,
March 1, 2008;
294(3):
C683 - C692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Tansky, C. Pothoulakis, and S. E. Leeman
Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor
PNAS,
June 19, 2007;
104(25):
10691 - 10696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Koon, D. Zhao, Y. Zhan, M. P. Moyer, and C. Pothoulakis
Substance P mediates antiapoptotic responses in human colonocytes by Akt activation
PNAS,
February 6, 2007;
104(6):
2013 - 2018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Koon, D. Zhao, Y. Zhan, S. H. Rhee, M. P. Moyer, and C. Pothoulakis
Substance P Stimulates Cyclooxygenase-2 and Prostaglandin E2 Expression through JAK-STAT Activation in Human Colonic Epithelial Cells.
J. Immunol.,
April 15, 2006;
176(8):
5050 - 5059.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Karagiannides, E. Kokkotou, M. Tansky, T. Tchkonia, N. Giorgadze, M. O'Brien, S. E. Leeman, J. L. Kirkland, and C. Pothoulakis
Induction of colitis causes inflammatory responses in fat depots: Evidence for substance P pathways in human mesenteric preadipocytes
PNAS,
March 28, 2006;
103(13):
5207 - 5212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Koon, D. Zhao, Y. Zhan, S. Simeonidis, M. P. Moyer, and C. Pothoulakis
Substance P-Stimulated Interleukin-8 Expression in Human Colonic Epithelial Cells Involves Protein Kinase C{delta} Activation
J. Pharmacol. Exp. Ther.,
September 1, 2005;
314(3):
1393 - 1400.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Brun, C. Mastrotto, E. Beggiao, A. Stefani, L. Barzon, G. C. Sturniolo, G. Palu, and I. Castagliuolo
Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation
Am J Physiol Gastrointest Liver Physiol,
April 1, 2005;
288(4):
G621 - G629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Koon, D. Zhao, X. Na, M. P. Moyer, and C. Pothoulakis
Metalloproteinases and Transforming Growth Factor-{alpha} Mediate Substance P-induced Mitogen-activated Protein Kinase Activation and Proliferation in Human Colonocytes
J. Biol. Chem.,
October 29, 2004;
279(44):
45519 - 45527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhao, Y. Zhan, H. W. Koon, H. Zeng, S. Keates, M. P. Moyer, and C. Pothoulakis
Metalloproteinase-dependent Transforming Growth Factor-{alpha} Release Mediates Neurotensin-stimulated MAP Kinase Activation in Human Colonic Epithelial Cells
J. Biol. Chem.,
October 15, 2004;
279(42):
43547 - 43554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Bertelsen, K. E. Barrett, and S. J. Keely
Gs Protein-coupled Receptor Agonists Induce Transactivation of the Epidermal Growth Factor Receptor in T84 Cells: IMPLICATIONS FOR EPITHELIAL SECRETORY RESPONSES
J. Biol. Chem.,
February 20, 2004;
279(8):
6271 - 6279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Olszewska-Pazdrak, K. L. Ives, J. Park, C. M. Townsend Jr., and M. R. Hellmich
Epidermal Growth Factor Potentiates Cholecystokinin/Gastrin Receptor-mediated Ca2+ Release by Activation of Mitogen-activated Protein Kinases
J. Biol. Chem.,
January 16, 2004;
279(3):
1853 - 1860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zimmer, M. Rohn, G. P. McGregor, M. Schemann, K.-K. Conzelmann, and G. Herrler
Virokinin, a Bioactive Peptide of the Tachykinin Family, Is Released from the Fusion Protein of Bovine Respiratory Syncytial Virus
J. Biol. Chem.,
November 21, 2003;
278(47):
46854 - 46861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tohgo, E. W. Choy, D. Gesty-Palmer, K. L. Pierce, S. Laporte, R. H. Oakley, M. G. Caron, R. J. Lefkowitz, and L. M. Luttrell
The Stability of the G Protein-coupled Receptor-beta -Arrestin Interaction Determines the Mechanism and Functional Consequence of ERK Activation
J. Biol. Chem.,
February 14, 2003;
278(8):
6258 - 6267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Keely and K. E. Barrett
p38 mitogen-activated protein kinase inhibits calcium-dependent chloride secretion in T84 colonic epithelial cells
Am J Physiol Cell Physiol,
February 1, 2003;
284(2):
C339 - C348.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Saban, N. P. Gerard, M. R. Saban, N.-B. Nguyen, D. J. DeBoer, and B. K. Wershil
Mast cells mediate substance P-induced bladder inflammation through an NK1 receptor-independent mechanism
Am J Physiol Renal Physiol,
October 1, 2002;
283(4):
F616 - F629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kumaran and K. Shivakumar
Calcium- and superoxide anion-mediated mitogenic action of substance P on cardiac fibroblasts
Am J Physiol Heart Circ Physiol,
May 1, 2002;
282(5):
H1855 - H1862.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Luttrell and R. J. Lefkowitz
The role of {beta}-arrestins in the termination and transduction of G-protein-coupled receptor signals
J. Cell Sci.,
January 2, 2002;
115(3):
455 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Keates, S. Sougioultzis, A. C. Keates, D. Zhao, R. M. Peek Jr., L. M. Shaw, and C. P. Kelly
cag+ Helicobacter pylori Induce Transactivation of the Epidermal Growth Factor Receptor in AGS Gastric Epithelial Cells
J. Biol. Chem.,
December 14, 2001;
276(51):
48127 - 48134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhao, A. C. Keates, S. Kuhnt-Moore, M. P. Moyer, C. P. Kelly, and C. Pothoulakis
Signal Transduction Pathways Mediating Neurotensin-stimulated Interleukin-8 Expression in Human Colonocytes
J. Biol. Chem.,
November 21, 2001;
276(48):
44464 - 44471.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|